Pharma-Bio Serv (PBSV) Net Income towards Common Stockholders (2016 - 2025)
Historic Net Income towards Common Stockholders for Pharma-Bio Serv (PBSV) over the last 16 years, with Q4 2025 value amounting to -$102.0.
- Pharma-Bio Serv's Net Income towards Common Stockholders fell 10063.31% to -$102.0 in Q4 2025 from the same period last year, while for Oct 2025 it was -$110021.0, marking a year-over-year increase of 8585.16%. This contributed to the annual value of -$100463.0 for FY2025, which is 8708.07% up from last year.
- According to the latest figures from Q4 2025, Pharma-Bio Serv's Net Income towards Common Stockholders is -$102.0, which was down 10063.31% from -$213808.0 recorded in Q3 2025.
- Pharma-Bio Serv's Net Income towards Common Stockholders' 5-year high stood at $2.3 million during Q3 2021, with a 5-year trough of -$4.9 million in Q4 2021.
- Over the past 5 years, Pharma-Bio Serv's median Net Income towards Common Stockholders value was $134366.0 (recorded in 2022), while the average stood at -$33000.8.
- Data for Pharma-Bio Serv's Net Income towards Common Stockholders shows a peak YoY increase of 22872.01% (in 2021) and a maximum YoY decrease of 347565.8% (in 2021) over the last 5 years.
- Pharma-Bio Serv's Net Income towards Common Stockholders (Quarter) stood at -$4.9 million in 2021, then soared by 103.56% to $173379.0 in 2022, then tumbled by 127.19% to -$47148.0 in 2023, then soared by 134.17% to $16111.0 in 2024, then tumbled by 100.63% to -$102.0 in 2025.
- Its last three reported values are -$102.0 in Q4 2025, -$213808.0 for Q3 2025, and $95353.0 during Q2 2025.